Pricing and Market Access

RWE begins where randomized controlled trials (RCTs) leave off in supporting differentiated value propositions.

In revealing the characteristics and costs associated with treating the target patient population, RWE gives marketers an understanding of their ultimate product’s value to the healthcare system. RWE can be used to set a product’s target price, reveal the total cost of care, and support value-based contracting and population health management. As life sciences companies prepare for product launch, they can rely on IQVIA specialists to:

• Conduct literature reviews
• Perform meta-analyses and indirect treatment comparisons
• Perform pricing analytics and willingness-to-pay studies
• Conduct internal and external reference pricing studies
• Engage stakeholders (patients, providers, and payers) in value proposition testing/validation
• Generate evidence
• Prepare and submit reimbursement and pricing dossiers
• Provide insights to support re-negotiated managed-entry agreements